Post–COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients

Peghin, Maddalena; Martino, Maria De; Palese, Alvisa; Gerussi, Valentina; Bontempo, Giulia; Graziano, Elena; Visintini, Erica; Elia, Denise D’; Dellai, Fabiana; Marrella, Francesco; Fabris, Martina; Curcio, Francesco; Sartor, Assunta; Isola, Miriam; Tascini, Carlo

doi:10.1016/j.cmi.2022.03.016

Cited by 43 publications

(70 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prospective cohort study conducted by Peghin et al [ 12 ] investigated the impact of vaccination on the development of long COVID symptoms. Participants were to be evaluated at baseline and then telephone-interviewed by the same trained nurses at 6 and 12 months using a standardized questionnaire.…”

Section: Resultsmentioning

confidence: 99%

COVID-19 Vaccine and Long COVID: A Scoping Review

Mumtaz¹,

Sheikh

Khan³

et al. 2022

Life

View full text Add to dashboard Cite

As the COVID-19 pandemic progresses, changing definitions and therapeutics regarding the post-acute sequela of COVID-19, particularly long COVID, have become a subject of great interest and study. The study aims to describe the pathophysiology and discuss different therapeutic agents currently available for long COVID. Another objective is to assess comparative efficacy between different types of vaccines on symptoms of long COVID. A preliminary search was conducted using Ovid Medline, Embase, medRxiv, and NIH COVID-19 portfolios. A total of 16 studies were included in our review. Despite some of the data showing variable results, most of the vaccinated patients reported improvement in long COVID symptoms with no significant difference between various types of vaccines. Further trials are needed to better identify the comparative efficacy of vaccines for long COVID and ascertain other therapeutic modalities.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19 Vaccine and Long COVID: A Scoping Review

Mumtaz¹,

Sheikh

Khan³

et al. 2022

Life

View full text Add to dashboard Cite

show abstract

“…We believe that the humoral response of asymptomatic patients provides interesting insights, since it could be the result of the complex balance between the individual immune state and the inflammatory response against SARS-CoV-2, manifesting itself in an asymptomatic acute infection and absence of development of post COVID-19 syndrome. Of note that in our cohort we found that 5.4% (3/55) and 7.2 %(4/55) asymptomatic patients at acute onset complained symptoms at 6 and 12 months follow-up respectively 4 5 . Interestingly, taking into consideration the limited size, two out of three and two out of four maintained serological response at 6 and 12 months post infection follow-up respectively.…”

mentioning

confidence: 43%

‘Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients’: authors' response

Peghin

Martino

Palese

et al. 2022

Clinical Microbiology and Infection

Self Cite

View full text Add to dashboard Cite

“…In einer Studie konnte eine Reduktion der Long-COVID-induziertenHausarztbesuche berichtet werden [36]. Zwei Studien konnten keinen Einfluss der Impfung auf Long-COVID nachweisen [37,38]. Eine Studie beschrieb Long-COVID nicht als Risikofaktor für eine erhöhte Reaktogenität der COVID-19-Impfung [39].…”

Section: Covid-19-impfung Als Therapeutische Option Bei Long-covidunclassified

Stellenwert der COVID-19-Impfung im Kontext von Long-COVID

Bauernfeind

Schmidt

2022

Innere Medizin

View full text Add to dashboard Cite

In diesem Beitrag-Postulierte Pathophysiologie von Impfung und Long-COVID -COVID-19-Impfung zur Prävention von Long-COVID Impfung vor SARS-CoV-2-Infektion • Impfung vor und/oder nach SARS-Co-V-2-Infektion -COVID-19-Impfung als therapeutische Option bei Long-COVID -Resümee QR-Code scannen & Beitrag online lesen Zusammenfassung Strategien zum Umgang mit Long-COVID (COVID "coronavirus disease") sind bislang nicht verfügbar. Eine der aktuell geprüften Optionen ist die COVID-19-Impfung, sowohl präventiv als auch therapeutisch. Die Bewertung der vorhandenen Studien ist durch uneinheitliche Definitionen erschwert. Es gibt jedoch Hinweise, dass die (vollständige) COVID-19-Impfung nicht nur die symptomatische Infektion verhindern kann, sondern auch das Risiko für Long-COVID bei Durchbruchinfektionen zu reduzieren vermag. Bei Patienten mit Long-COVID führt die anschließende (einfache und/oder zweifache) COVID-19-Impfung teilweise zu einer Symptommodifikation, die bisweilen nur passager ist. Ein therapeutischer Effekt kann aus der vorliegenden Evidenz allerdings nicht sicher abgeleitet werden. Schlüsselwörter Long-COVID-Prävention • Long-COVID-Therapie • COVID-19-Impfung • Durchbruchsinfektion • "Severe acute respiratory syndrome coronavirus type 2" (SARS-CoV-2) Keywords Long COVID/prevention • Long COVID/therapy • COVID-19 vaccination • Breakthrough infection • "Severe acute respiratory syndrome coronavirus type 2" (SARS-CoV-2)

show abstract

Post–COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients

Cited by 43 publications

References 33 publications

COVID-19 Vaccine and Long COVID: A Scoping Review

COVID-19 Vaccine and Long COVID: A Scoping Review

‘Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients’: authors' response

Stellenwert der COVID-19-Impfung im Kontext von Long-COVID

Contact Info

Product

Resources

About